NASDAQ:MORF Morphic (MORF) Stock Price, News & Analysis $56.99 0.00 (0.00%) (As of 08/16/2024) Add Compare Share Share Today's Range$56.99▼$56.9950-Day Range$31.28▼$56.9952-Week Range$19.34▼$57.00Volume400 shsAverage Volume1.27 million shsMarket Capitalization$2.85 billionP/E RatioN/ADividend YieldN/APrice Target$54.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Morphic alerts: Email Address Morphic MarketRank™ Stock AnalysisAnalyst RatingHold2.29 Rating ScoreUpside/Downside4.8% Downside$54.25 Price TargetShort InterestHealthy3.79% of Shares Sold ShortDividend StrengthN/ASustainability-0.57Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$7.02 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.07) to ($4.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.12 out of 5 starsMedical Sector483rd out of 910 stocksPharmaceutical Preparations Industry227th out of 426 stocks 1.1 Analyst's Opinion Consensus RatingMorphic has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageMorphic has only been the subject of 4 research reports in the past 90 days.Read more about Morphic's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.79% of the outstanding shares of Morphic have been sold short.Short Interest Ratio / Days to CoverMorphic has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Morphic has recently increased by 13.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMorphic does not currently pay a dividend.Dividend GrowthMorphic does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMorphic has received a 76.58% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Morphic is -0.57. Previous Next N/A News and Social Media Coverage Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Morphic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,018,566.00 in company stock.Percentage Held by Insiders25.60% of the stock of Morphic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.25% of the stock of Morphic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Morphic's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Morphic are expected to decrease in the coming year, from ($4.07) to ($4.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Morphic is -16.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Morphic is -16.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMorphic has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Morphic's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Morphic Stock (NASDAQ:MORF)Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More MORF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MORF Stock News HeadlinesAugust 31, 2024 | americanbankingnews.comAnalysts Set Morphic Holding, Inc. (NASDAQ:MORF) Target Price at $54.25August 19, 2024 | finance.yahoo.comEli Lilly acquires Morphic in IBD portfolio expansionSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 17, 2024 | finance.yahoo.comMORF Jan 2025 25.000 put (MORF250117P00025000)August 16, 2024 | prnewswire.comLilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel DiseaseAugust 8, 2024 | globenewswire.comCalling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesAugust 6, 2024 | investing.comMorphic Holding (MORF) Earnings Dates & ReportsAugust 2, 2024 | globenewswire.comCalling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…July 31, 2024 | morningstar.comMorphic Holding Inc MORFJuly 31, 2024 | globenewswire.comMORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Holding, Inc., in the U.S. District Court for the Northern District of CaliforniaJuly 28, 2024 | globenewswire.comCalling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesJuly 26, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)July 25, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MORF, AGR, SHCR, DRQ on Behalf of ShareholdersJuly 23, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Morphic Holding, Inc. - MORFJuly 22, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Hold Rating on Morphic Holding (MORF)July 20, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCR, MORF on Behalf of ShareholdersJuly 19, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Morphic Holding, Inc. – MORFSee More Headlines Receive MORF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/25/2024Today9/07/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MORF CUSIPN/A CIK1679363 Webwww.morphictx.com Phone(781) 996-0955FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$54.25 High Stock Price Target$57.00 Low Stock Price Target$46.00 Potential Upside/Downside-4.8%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,100,000.00 Net MarginsN/A Pretax Margin-29,119.96% Return on Equity-26.62% Return on Assets-25.74% Debt Debt-to-Equity RatioN/A Current Ratio24.13 Quick Ratio24.13 Sales & Book Value Annual Sales$520,000.00 Price / Sales5,490.11 Cash FlowN/A Price / Cash FlowN/A Book Value$12.31 per share Price / Book4.63Miscellaneous Outstanding Shares50,094,000Free Float37,270,000Market Cap$2.85 billion OptionableOptionable Beta1.49 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Bruce N. Rogers Ph.D. (Age 55)President & Interim Principal Executive Officer Comp: $787.88kDr. Timothy A. Springer Ph.D. (Age 76)Founder, Independent Director & Member of Scientific Advisory Board Comp: $40kDr. Marc Schegerin M.B.A. (Age 48)M.D., CFO & COO Comp: $722.38kDr. Praveen P. Tipirneni M.D. (Age 55)CEO, MD & Director (Leave of Absence) Comp: $991.33kMr. Robert E. Farrell Jr. (Age 59)CPA, Senior VP of Finance & Chief Accounting Officer Dr. Blaise Lippa Ph.D.Chief Scientific OfficerMr. William D. DeVaul Esq. (Age 53)General Counsel & Secretary Comp: $601.44kMr. Aaron PeltaSenior Vice President of Business & Corporate DevelopmentMs. Joanne GibbonsSenior Vice President of Regulatory AffairsDr. Simon Cooper MBBS (Age 54)Chief Medical Officer More ExecutivesKey CompetitorsArvinasNASDAQ:ARVNSyndax PharmaceuticalsNASDAQ:SNDXRedHill BiopharmaNASDAQ:RDHLCatalentNYSE:CTLTLegend BiotechNASDAQ:LEGNView All CompetitorsInsiders & InstitutionsNovo Holdings A SBought 375,000 shares on 8/20/2024Ownership: 0.749%Algert Global LLCBought 16,531 shares on 8/16/2024Ownership: 0.066%Affinity Asset Advisors LLCBought 25,573 shares on 8/15/2024Ownership: 0.500%The Manufacturers Life Insurance Company Bought 4,021 shares on 8/15/2024Ownership: 0.172%ProShare Advisors LLCSold 1,828 shares on 8/14/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions MORF Stock Analysis - Frequently Asked Questions How have MORF shares performed this year? Morphic's stock was trading at $28.88 at the beginning of the year. Since then, MORF stock has increased by 97.3% and is now trading at $56.99. View the best growth stocks for 2024 here. How were Morphic's earnings last quarter? Morphic Holding, Inc. (NASDAQ:MORF) posted its quarterly earnings results on Thursday, July, 25th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by $0.19. When did Morphic IPO? Morphic (MORF) raised $75 million in an initial public offering on Thursday, June 27th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO. Who are Morphic's major shareholders? Morphic's top institutional investors include Point72 Asset Management L.P. (2.92%), Novo Holdings A S (0.75%), Affinity Asset Advisors LLC (0.50%) and Candriam S.C.A. (0.43%). Insiders that own company stock include Timothy A Springer, Bruce Rogers, Praveen P Tipirneni, Marc Schegerin, William Devaul, Robert E Farrell, Jr, Robert E Farrell Jr, Joseph P Slattery and Peter Linde. View institutional ownership trends. How do I buy shares of Morphic? Shares of MORF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Morphic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Morphic investors own include Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), AVEO Pharmaceuticals (AVEO), Atreca (BCEL), CymaBay Therapeutics (CBAY), Chiasma (CHMA) and Clovis Oncology (CLVS). This page (NASDAQ:MORF) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Morphic Holding, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Morphic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
